The goals of this project are to: (1) fully characterize SIRD as a distinct form of organ failure impairing O2 delivery in sepsis, (2) elucidate SIRD's role in multiple organ failure (MOF) progression, and (3) evaluate a mechanism-based therapy targeted to SIRD pathobiology. In sepsis, a number of RBC defects have been (individually) described: altered O2 affinity, membrane deformability, RBC aggregation and adhesion, as well as dysregulated RBC-based nitric oxide (NO) processing. We suggest that these defects comprise a unique class of organ failure (which we term SiRD) that disables transport of O2 from lungs to tissue. Based upon our preliminary findings, we propose the novel hypothesis that in sepsis, energetic support of RBC antioxidant systems fails, with SiRD arising consequent to unquenched reactive oxygen species (ROS) generated in the course of hemoglobin O2 binding/release. As such, by critically impairing O2 delivery (by limiting both delivery of RBCs to tissue [e.g. flow] and release of O2 from delivered RBCs), SiRD exacerbates dysoxia and MOF progression. We propose a mechanistic 'reverse translational' approach to test this hypothesis in a comprehensively phenotyped cohort of children with severe sepsis (enabling us to study subjects lacking comorbidities which also impair RBC function, e.g. diabetes, renal failure, etc.). We will study children in the Inflammation Phenotypes in Pediatric Sepsis Induced Multiple Organ Failure (PHENOMS Trial [GM108618], which will be conducted by the NICHD Collaborative Pediatric Critical Care Research Network [CPCCRN]). This will enable us to leverage the established CPCCRN infrastructure and the detailed phenotype and outcome evaluation of the PHENOMS cohort so that we may link SiRD to progression of sepsis syndromes, MOF evolution, and to outcome. We will structure our approach by pursuing the following Specific Aims: SA1. Define sepsis-induced biochemical alterations to RBCs that influence O2 delivery. PHENOMS subjects' RBCs will be studied in ex vivo assay platforms, organ bioassays and in vivo models to quantitate defects in (and efficacy of SOD mimetics in restoring): O2 binding/delivery as well as control of vascular tone and blood flow. SA2 Define sepsis-induced biophysical alterations to RBCs that influence O2 delivery. As above, subjects' RBCs will be studied employing state of the art biophysical analysis (for membrane deformability, RBC aggregation and endothelial adhesion) and intravital microscopy to quantitate defects in (and efficacy of SOD mimetics in restoring): RBC transit through vascular channels and adhesion to activated endothelium. SA3 Characterize sepsis-induced alterations in RBC energy metabolism, antioxidant systems and oxidative injury. Study subjects' RBCs will be subjected to controlled oxidative loading to quantitate the dynamic range in (and efficacy of SOD mimetics in restoring): glycolytic flux (1H NMR analysis of lactate isotopomers), redox poise in antioxidant systems, and (c) oxidative injury to membrane and proteins.

Public Health Relevance

The goals of this project are to study a national cohort of septic children without chronic co-morbidities, so that we may: (1) fully characterize sepsis-induced red cell dysfunction (SiRD) as a distinct form of organ failure impairing O2 delivery in sepsis, (2) elucidate SIRD's role in multiple organ failure (MOF) progression, and (3) evaluate efficacy of SOD mimetics as a mechanism-based therapy targeted to SIRD pathobiology.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM113838-02
Application #
9069918
Study Section
Special Emphasis Panel (ZHL1)
Program Officer
Dunsmore, Sarah
Project Start
2015-06-01
Project End
2020-01-31
Budget Start
2016-02-01
Budget End
2017-01-31
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Washington University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Vostal, Jaroslav G; Buehler, Paul W; Gelderman, Monique P et al. (2018) Proceedings of the Food and Drug Administration's public workshop on new red blood cell product regulatory science 2016. Transfusion 58:255-266
Davila, Sam; Halstead, E Scott; Hall, Mark W et al. (2018) Viral DNAemia and Immune Suppression in Pediatric Sepsis. Pediatr Crit Care Med 19:e14-e22
Mistry, Nikhil; Mazer, C David; Sled, John G et al. (2018) Red blood cell antibody-induced anemia causes differential degrees of tissue hypoxia in kidney and brain. Am J Physiol Regul Integr Comp Physiol 314:R611-R622
Nemkov, Travis; Sun, Kaiqi; Reisz, Julie A et al. (2018) Hypoxia modulates the purine salvage pathway and decreases red blood cell and supernatant levels of hypoxanthine during refrigerated storage. Haematologica 103:361-372
Steffen, Katherine; Doctor, Allan; Hoerr, Julie et al. (2017) Controlling Phlebotomy Volume Diminishes PICU Transfusion: Implementation Processes and Impact. Pediatrics 140:
Doctor, Allan; Zimmerman, Jerry; Agus, Michael et al. (2017) Pediatric Multiple Organ Dysfunction Syndrome: Promising Therapies. Pediatr Crit Care Med 18:S67-S82
Carcillo, Joseph A; Halstead, E Scott; Hall, Mark W et al. (2017) Three Hypothetical Inflammation Pathobiology Phenotypes and Pediatric Sepsis-Induced Multiple Organ Failure Outcome. Pediatr Crit Care Med 18:513-523
Dosier, Laura Beth Mann; Premkumar, Vikram J; Zhu, Hongmei et al. (2017) Antagonists of the system L neutral amino acid transporter (LAT) promote endothelial adhesivity of human red blood cells. Thromb Haemost 117:1402-1411
Said, Ahmed S; Doctor, Allan (2017) Influence of red blood cell-derived microparticles upon vasoregulation. Blood Transfus 15:522-534
Markham, Chris; Small, Sara; Hovmand, Peter et al. (2017) Transfusion Decision Making in Pediatric Critical Illness. Pediatr Clin North Am 64:991-1015

Showing the most recent 10 out of 21 publications